<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01984697</url>
  </required_header>
  <id_info>
    <org_study_id>V503-010</org_study_id>
    <secondary_id>2013-001314-15</secondary_id>
    <secondary_id>V503-010</secondary_id>
    <nct_id>NCT01984697</nct_id>
  </id_info>
  <brief_title>A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)</brief_title>
  <official_title>A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose Regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Administered in Preadolescents and Adolescents (9 to 14 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a 37-month safety and immunogenicity study conducted in boys and girls 9 to 14 years
      of age and in young women 16 to 26 years of age. From this study, the goal was to establish
      that the investigational 2-dose regimens (0, 6 months and 0, 12 months) studied in boys and
      girls 9 to 14 years of age are generally safe and immunogenic, with an antibody response that
      is not inferior to that observed in young women 16 to 26 years of age who received the
      standard 3-dose regimen of V503 (i.e., the population and dose regimen used to establish V503
      efficacy).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2013</start_date>
  <completion_date type="Actual">July 24, 2017</completion_date>
  <primary_completion_date type="Actual">June 19, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 After the Last Dose of V503 in the Planned Regimen</measure>
    <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
    <description>Antibodies to HPV virus-like particles (VLP) type 6 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen</measure>
    <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
    <description>Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen</measure>
    <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
    <description>Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen</measure>
    <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
    <description>Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen</measure>
    <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
    <description>Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen</measure>
    <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
    <description>Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen</measure>
    <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
    <description>Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen</measure>
    <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
    <description>Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen</measure>
    <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
    <description>Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion to HPV Type 6 at Four Weeks After the Last Dose of V503 in the Planned Regimen</measure>
    <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
    <description>Antibodies to HPV VLP type 6 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 6 was defined as a titer &gt;=30 mMU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen</measure>
    <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
    <description>Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 11 was defined as a titer &gt;=16 mMU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen</measure>
    <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
    <description>Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 16 was defined as a titer &gt;=20 mMU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen</measure>
    <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
    <description>Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 18 was defined as a titer &gt;=24 mMU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen</measure>
    <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
    <description>Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 31 was defined as a titer &gt;=10 mMU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen</measure>
    <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
    <description>Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 33 was defined as a titer &gt;=8 mMU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen</measure>
    <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
    <description>Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 45 was defined as a titer &gt;=8 mMU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen</measure>
    <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
    <description>Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 52 was defined as a titer &gt;=8 mMU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen</measure>
    <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
    <description>Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 58 was defined as a titer &gt;=8 mMU/mL.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24</measure>
    <time_frame>Month 24</time_frame>
    <description>Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
  </other_outcome>
  <other_outcome>
    <measure>Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24</measure>
    <time_frame>Month 24</time_frame>
    <description>Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Seroconversion to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were defined as a titer &gt;=41, 24, 34, 39, 24, 18, 12, 16, and 12 mMU/mL, respectively. These cutoffs differ from analyses performed on samples collected up to Month 13; the antibody persistence analysis employed a new version of the assay.</description>
  </other_outcome>
  <other_outcome>
    <measure>Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36</measure>
    <time_frame>Month 36</time_frame>
    <description>Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
  </other_outcome>
  <other_outcome>
    <measure>Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36</measure>
    <time_frame>Month 36</time_frame>
    <description>Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Seroconversion to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were defined as a titer &gt;=41, 24, 34, 39, 24, 18, 12, 16, and 12 mMU/mL, respectively. These cutoffs differ from analyses performed on samples collected up to Month 13; the antibody persistence analysis employed a new version of the assay.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1518</enrollment>
  <condition>Human Papillomavirus Infection</condition>
  <arm_group>
    <arm_group_label>Girls 9 to 14 Years V503 at Months 0 and 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Boys 9 to 14 Years V503 at Months 0 and 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Girls 9 to 14 Years V503 at Months 0, 2, and 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)</intervention_name>
    <description>V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection</description>
    <arm_group_label>Boys 9 to 14 Years V503 at Months 0 and 6</arm_group_label>
    <arm_group_label>Girls 9 to 14 Years V503 at Months 0 and 6</arm_group_label>
    <arm_group_label>Girls 9 to 14 Years V503 at Months 0, 2, and 6</arm_group_label>
    <arm_group_label>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</arm_group_label>
    <arm_group_label>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All Participants:

        -Judged to be in good physical health on the basis of medical history, physical examination
        and laboratory results

        Boys and Girls 9 to 14 Years:

        -Must not have had coitarche and does not plan on becoming sexually active during the
        vaccination period

        Women 16 to 26 Years:

          -  Has never had a Papanicolaou (Pap) test or only had normal Pap test results

          -  A lifetime history of 0 to 4 male and/or female sexual partners

        Exclusion Criteria:

        All Participants:

          -  Known allergy to any vaccine component

          -  History of severe allergic reaction that required medical intervention

          -  Thrombocytopenia or any coagulation disorder

          -  Females only: participant is pregnant or expecting to donate eggs during day 1 through
             month 7

          -  Currently immunocompromised, or been diagnosed with immunodeficiency

          -  Had a splenectomy

          -  Receiving or has received immunosuppressive therapies within the last year

          -  Received any immunoglobulin product or blood-derived product within 3 months

          -  Received a marketed HPV vaccine or has participated in an HPV vaccine clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Norway</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Iversen OE, Miranda MJ, Ulied A, Soerdal T, Lazarus E, Chokephaibulkit K, Block SL, Skrivanek A, Nur Azurah AG, Fong SM, Dvorak V, Kim KH, Cestero RM, Berkovitch M, Ceyhan M, Ellison MC, Ritter MA, Yuan SS, DiNubile MJ, Saah AJ, Luxembourg A. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women. JAMA. 2016 Dec 13;316(22):2411-2421. doi: 10.1001/jama.2016.17615.</citation>
    <PMID>27893068</PMID>
  </results_reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>November 8, 2013</study_first_submitted>
  <study_first_submitted_qc>November 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2013</study_first_posted>
  <results_first_submitted>March 23, 2016</results_first_submitted>
  <results_first_submitted_qc>March 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 26, 2016</results_first_posted>
  <last_update_submitted>July 12, 2018</last_update_submitted>
  <last_update_submitted_qc>July 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 1536 participants were screened and 1518 were randomized into the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
          <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
        </group>
        <group group_id="P2">
          <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
          <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
        </group>
        <group group_id="P3">
          <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
          <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
        </group>
        <group group_id="P4">
          <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
          <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
        </group>
        <group group_id="P5">
          <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
          <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="301"/>
                <participants group_id="P2" count="301"/>
                <participants group_id="P3" count="301"/>
                <participants group_id="P4" count="301"/>
                <participants group_id="P5" count="314"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 1</title>
              <participants_list>
                <participants group_id="P1" count="301"/>
                <participants group_id="P2" count="301"/>
                <participants group_id="P3" count="300"/>
                <participants group_id="P4" count="300"/>
                <participants group_id="P5" count="314"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 2</title>
              <participants_list>
                <participants group_id="P1" count="293"/>
                <participants group_id="P2" count="296"/>
                <participants group_id="P3" count="291"/>
                <participants group_id="P4" count="298"/>
                <participants group_id="P5" count="313"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 3</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="293"/>
                <participants group_id="P5" count="311"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Month 36 Vaccination</title>
              <participants_list>
                <participants group_id="P1" count="270"/>
                <participants group_id="P2" count="281"/>
                <participants group_id="P3" count="280"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="258"/>
                <participants group_id="P2" count="270"/>
                <participants group_id="P3" count="272"/>
                <participants group_id="P4" count="280"/>
                <participants group_id="P5" count="279"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed last follow-up visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
          <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
        </group>
        <group group_id="B2">
          <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
          <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
        </group>
        <group group_id="B3">
          <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
          <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
        </group>
        <group group_id="B4">
          <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
          <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
        </group>
        <group group_id="B5">
          <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
          <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="301"/>
            <count group_id="B2" value="301"/>
            <count group_id="B3" value="301"/>
            <count group_id="B4" value="301"/>
            <count group_id="B5" value="314"/>
            <count group_id="B6" value="1518"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.4" spread="1.7"/>
                    <measurement group_id="B2" value="11.5" spread="1.7"/>
                    <measurement group_id="B3" value="11.4" spread="1.6"/>
                    <measurement group_id="B4" value="11.4" spread="1.7"/>
                    <measurement group_id="B5" value="21.0" spread="2.7"/>
                    <measurement group_id="B6" value="13.4" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 9 and 10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="101"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 11 and 12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="100"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 13 and 14 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="100"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 16 and 26 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="314"/>
                    <measurement group_id="B6" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="301"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="151"/>
                    <measurement group_id="B4" value="301"/>
                    <measurement group_id="B5" value="314"/>
                    <measurement group_id="B6" value="1067"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="301"/>
                    <measurement group_id="B3" value="150"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 After the Last Dose of V503 in the Planned Regimen</title>
        <description>Antibodies to HPV virus-like particles (VLP) type 6 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
        <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 After the Last Dose of V503 in the Planned Regimen</title>
          <description>Antibodies to HPV virus-like particles (VLP) type 6 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="257"/>
                <count group_id="O4" value="254"/>
                <count group_id="O5" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1657.9" lower_limit="1479.6" upper_limit="1857.6"/>
                    <measurement group_id="O2" value="1557.4" lower_limit="1391.5" upper_limit="1743.1"/>
                    <measurement group_id="O3" value="2678.8" lower_limit="2390.2" upper_limit="3002.1"/>
                    <measurement group_id="O4" value="1496.1" lower_limit="1334.1" upper_limit="1677.8"/>
                    <measurement group_id="O5" value="770.9" lower_limit="684.8" upper_limit="867.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the Geometric Mean Titer (GMT) ratio for Girls 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>2.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.83</ci_lower_limit>
            <ci_upper_limit>2.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Boys 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>2.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.73</ci_lower_limit>
            <ci_upper_limit>2.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Girls and Boys 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>3.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.93</ci_lower_limit>
            <ci_upper_limit>4.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion to HPV Type 6 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
        <description>Antibodies to HPV VLP type 6 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 6 was defined as a titer &gt;=30 mMU/mL.</description>
        <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion to HPV Type 6 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
          <description>Antibodies to HPV VLP type 6 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 6 was defined as a titer &gt;=30 mMU/mL.</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="257"/>
                <count group_id="O4" value="254"/>
                <count group_id="O5" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.9" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O4" value="99.2" lower_limit="97.2" upper_limit="99.9"/>
                    <measurement group_id="O5" value="99.6" lower_limit="97.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Girls 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Boys 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Girls and Boys 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
        <description>Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
        <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
          <description>Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="264"/>
                <count group_id="O3" value="257"/>
                <count group_id="O4" value="254"/>
                <count group_id="O5" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1388.9" lower_limit="1240.4" upper_limit="1555.3"/>
                    <measurement group_id="O2" value="1423.9" lower_limit="1273.2" upper_limit="1592.3"/>
                    <measurement group_id="O3" value="2941.8" lower_limit="2626.6" upper_limit="3294.9"/>
                    <measurement group_id="O4" value="1306.3" lower_limit="1165.5" upper_limit="1464.0"/>
                    <measurement group_id="O5" value="580.5" lower_limit="516.0" upper_limit="653.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Girls 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>2.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.03</ci_lower_limit>
            <ci_upper_limit>2.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Boys 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>2.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.09</ci_lower_limit>
            <ci_upper_limit>2.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Girls and Boys 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>5.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.32</ci_lower_limit>
            <ci_upper_limit>5.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
        <description>Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
        <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
          <description>Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="273"/>
                <count group_id="O3" value="264"/>
                <count group_id="O4" value="269"/>
                <count group_id="O5" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8004.9" lower_limit="7160.5" upper_limit="8948.8"/>
                    <measurement group_id="O2" value="8474.8" lower_limit="7582.4" upper_limit="9472.3"/>
                    <measurement group_id="O3" value="14329.3" lower_limit="12796.4" upper_limit="16045.9"/>
                    <measurement group_id="O4" value="6996.0" lower_limit="6254.1" upper_limit="7825.8"/>
                    <measurement group_id="O5" value="3154.0" lower_limit="2807.1" upper_limit="3543.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Girls 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>2.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.14</ci_lower_limit>
            <ci_upper_limit>3.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Boys 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>2.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.29</ci_lower_limit>
            <ci_upper_limit>3.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Girls and Boys 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>4.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.84</ci_lower_limit>
            <ci_upper_limit>5.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
        <description>Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
        <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
          <description>Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="272"/>
                <count group_id="O3" value="266"/>
                <count group_id="O4" value="270"/>
                <count group_id="O5" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1872.8" lower_limit="1651.6" upper_limit="2123.6"/>
                    <measurement group_id="O2" value="1860.9" lower_limit="1641.1" upper_limit="2110.2"/>
                    <measurement group_id="O3" value="2810.4" lower_limit="2474.9" upper_limit="3191.3"/>
                    <measurement group_id="O4" value="2049.3" lower_limit="1806.4" upper_limit="2324.8"/>
                    <measurement group_id="O5" value="761.5" lower_limit="670.8" upper_limit="864.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Girls 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>2.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.05</ci_lower_limit>
            <ci_upper_limit>2.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Boys 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>2.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.04</ci_lower_limit>
            <ci_upper_limit>2.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Girls and Boys 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>3.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.06</ci_lower_limit>
            <ci_upper_limit>4.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
        <description>Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
        <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
          <description>Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="268"/>
                <count group_id="O4" value="271"/>
                <count group_id="O5" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1436.3" lower_limit="1272.1" upper_limit="1621.8"/>
                    <measurement group_id="O2" value="1498.2" lower_limit="1326.5" upper_limit="1692.0"/>
                    <measurement group_id="O3" value="2117.5" lower_limit="1873.7" upper_limit="2393.1"/>
                    <measurement group_id="O4" value="1748.3" lower_limit="1548.1" upper_limit="1974.5"/>
                    <measurement group_id="O5" value="572.1" lower_limit="505.8" upper_limit="647.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Girls 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>2.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.10</ci_lower_limit>
            <ci_upper_limit>3.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Boys 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>2.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.20</ci_lower_limit>
            <ci_upper_limit>3.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Girls and Boys 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>3.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.08</ci_lower_limit>
            <ci_upper_limit>4.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
        <description>Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
        <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
          <description>Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="269"/>
                <count group_id="O4" value="275"/>
                <count group_id="O5" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1030.0" lower_limit="920.4" upper_limit="1152.7"/>
                    <measurement group_id="O2" value="1040.0" lower_limit="928.9" upper_limit="1164.3"/>
                    <measurement group_id="O3" value="2197.5" lower_limit="1961.9" upper_limit="2461.3"/>
                    <measurement group_id="O4" value="796.4" lower_limit="712.0" upper_limit="890.9"/>
                    <measurement group_id="O5" value="348.1" lower_limit="311.5" upper_limit="389.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Girls 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>2.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.50</ci_lower_limit>
            <ci_upper_limit>3.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Boys 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>2.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.55</ci_lower_limit>
            <ci_upper_limit>3.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Girls and Boys 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>6.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.36</ci_lower_limit>
            <ci_upper_limit>7.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
        <description>Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
        <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
          <description>Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="273"/>
                <count group_id="O3" value="268"/>
                <count group_id="O4" value="275"/>
                <count group_id="O5" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="357.6" lower_limit="313.7" upper_limit="407.6"/>
                    <measurement group_id="O2" value="352.3" lower_limit="309.0" upper_limit="401.7"/>
                    <measurement group_id="O3" value="417.7" lower_limit="365.9" upper_limit="476.9"/>
                    <measurement group_id="O4" value="661.7" lower_limit="580.6" upper_limit="754.1"/>
                    <measurement group_id="O5" value="213.6" lower_limit="187.7" upper_limit="243.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Girls 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.38</ci_lower_limit>
            <ci_upper_limit>2.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Boys 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.37</ci_lower_limit>
            <ci_upper_limit>1.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Girls and Boys 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.61</ci_lower_limit>
            <ci_upper_limit>2.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
        <description>Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
        <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
          <description>Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="273"/>
                <count group_id="O3" value="268"/>
                <count group_id="O4" value="275"/>
                <count group_id="O5" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="581.1" lower_limit="521.9" upper_limit="647.1"/>
                    <measurement group_id="O2" value="640.4" lower_limit="575.2" upper_limit="713.0"/>
                    <measurement group_id="O3" value="1123.4" lower_limit="1008.1" upper_limit="1251.9"/>
                    <measurement group_id="O4" value="909.9" lower_limit="817.6" upper_limit="1012.5"/>
                    <measurement group_id="O5" value="364.2" lower_limit="327.0" upper_limit="405.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Girls 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.36</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Boys 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.51</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Girls and Boys 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>3.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.64</ci_lower_limit>
            <ci_upper_limit>3.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
        <description>Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
        <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
          <description>Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="270"/>
                <count group_id="O3" value="265"/>
                <count group_id="O4" value="273"/>
                <count group_id="O5" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1251.2" lower_limit="1119.6" upper_limit="1398.4"/>
                    <measurement group_id="O2" value="1325.7" lower_limit="1186.2" upper_limit="1481.6"/>
                    <measurement group_id="O3" value="2444.6" lower_limit="2185.2" upper_limit="2734.9"/>
                    <measurement group_id="O4" value="1229.3" lower_limit="1100.7" upper_limit="1373.0"/>
                    <measurement group_id="O5" value="491.1" lower_limit="438.6" upper_limit="549.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Girls 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>2.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.15</ci_lower_limit>
            <ci_upper_limit>3.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Boys 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>2.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.30</ci_lower_limit>
            <ci_upper_limit>3.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the GMT ratio for Girls and Boys 9 to 14 Years / Young Women 16 to 26 years is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>4.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.23</ci_lower_limit>
            <ci_upper_limit>5.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
        <description>Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 11 was defined as a titer &gt;=16 mMU/mL.</description>
        <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
          <description>Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 11 was defined as a titer &gt;=16 mMU/mL.</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="264"/>
                <count group_id="O3" value="257"/>
                <count group_id="O4" value="254"/>
                <count group_id="O5" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O4" value="99.6" lower_limit="97.8" upper_limit="100"/>
                    <measurement group_id="O5" value="99.6" lower_limit="97.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Girls 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Boys 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Girls and Boys 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
        <description>Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 16 was defined as a titer &gt;=20 mMU/mL.</description>
        <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
          <description>Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 16 was defined as a titer &gt;=20 mMU/mL.</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="273"/>
                <count group_id="O3" value="264"/>
                <count group_id="O4" value="269"/>
                <count group_id="O5" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.7" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98.7" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O5" value="99.6" lower_limit="97.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Girls 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Boys 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Girls and Boys 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
        <description>Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 18 was defined as a titer &gt;=24 mMU/mL.</description>
        <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
          <description>Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 18 was defined as a titer &gt;=24 mMU/mL.</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="272"/>
                <count group_id="O3" value="266"/>
                <count group_id="O4" value="270"/>
                <count group_id="O5" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.7" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98.7" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O4" value="99.6" lower_limit="98.0" upper_limit="100"/>
                    <measurement group_id="O5" value="98.5" lower_limit="96.2" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Girls 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Boys 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Girls and Boys 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
        <description>Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 31 was defined as a titer &gt;=10 mMU/mL.</description>
        <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
          <description>Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 31 was defined as a titer &gt;=10 mMU/mL.</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="268"/>
                <count group_id="O4" value="271"/>
                <count group_id="O5" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="98.0" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O5" value="99.6" lower_limit="97.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Girls 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Boys 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Girls and Boys 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
        <description>Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 33 was defined as a titer &gt;=8 mMU/mL.</description>
        <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
          <description>Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 33 was defined as a titer &gt;=8 mMU/mL.</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="269"/>
                <count group_id="O4" value="275"/>
                <count group_id="O5" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="98.0" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="98.7" upper_limit="100"/>
                    <measurement group_id="O5" value="99.6" lower_limit="98.0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Girls 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Boys 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Girls and Boys 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
        <description>Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 45 was defined as a titer &gt;=8 mMU/mL.</description>
        <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
          <description>Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 45 was defined as a titer &gt;=8 mMU/mL.</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="273"/>
                <count group_id="O3" value="268"/>
                <count group_id="O4" value="275"/>
                <count group_id="O5" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="97.4" upper_limit="99.9"/>
                    <measurement group_id="O2" value="99.3" lower_limit="97.4" upper_limit="99.9"/>
                    <measurement group_id="O3" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O4" value="99.3" lower_limit="97.4" upper_limit="99.9"/>
                    <measurement group_id="O5" value="97.9" lower_limit="95.4" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Girls 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Boys 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Girls and Boys 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>4.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
        <description>Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 52 was defined as a titer &gt;=8 mMU/mL.</description>
        <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
          <description>Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 52 was defined as a titer &gt;=8 mMU/mL.</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="273"/>
                <count group_id="O3" value="268"/>
                <count group_id="O4" value="275"/>
                <count group_id="O5" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="98.0" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98.7" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O4" value="99.6" lower_limit="98.0" upper_limit="100"/>
                    <measurement group_id="O5" value="99.6" lower_limit="98.0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Girls 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Boys 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Girls and Boys 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
        <description>Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 58 was defined as a titer &gt;=8 mMU/mL.</description>
        <time_frame>4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen</title>
          <description>Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 58 was defined as a titer &gt;=8 mMU/mL.</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="270"/>
                <count group_id="O3" value="265"/>
                <count group_id="O4" value="273"/>
                <count group_id="O5" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O4" value="99.6" lower_limit="98.0" upper_limit="100"/>
                    <measurement group_id="O5" value="99.6" lower_limit="97.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Girls 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Boys 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the lower limit of the 95% confidence interval of the seroconversion percentage difference for Girls and Boys 9 to 14 Years - Young Women 16 to 26 years is &gt; -5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>One-sided non-inferiority test at alpha=0.025 level</method_desc>
            <param_type>Seroconversion percentage difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24</title>
        <description>Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
        <time_frame>Month 24</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV types, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24</title>
          <description>Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV types, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="301"/>
                <count group_id="O3" value="300"/>
                <count group_id="O4" value="300"/>
                <count group_id="O5" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV Type 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="259"/>
                    <count group_id="O3" value="252"/>
                    <count group_id="O4" value="249"/>
                    <count group_id="O5" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260.7" lower_limit="231.5" upper_limit="293.6"/>
                    <measurement group_id="O2" value="209.1" lower_limit="185.9" upper_limit="235.1"/>
                    <measurement group_id="O3" value="574.0" lower_limit="509.6" upper_limit="646.5"/>
                    <measurement group_id="O4" value="300.7" lower_limit="266.8" upper_limit="339.0"/>
                    <measurement group_id="O5" value="153.2" lower_limit="135.4" upper_limit="173.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="260"/>
                    <count group_id="O3" value="252"/>
                    <count group_id="O4" value="249"/>
                    <count group_id="O5" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.8" lower_limit="150.5" upper_limit="191.7"/>
                    <measurement group_id="O2" value="150.6" lower_limit="133.6" upper_limit="169.7"/>
                    <measurement group_id="O3" value="443.7" lower_limit="392.9" upper_limit="501.0"/>
                    <measurement group_id="O4" value="201.9" lower_limit="178.7" upper_limit="228.1"/>
                    <measurement group_id="O5" value="98.3" lower_limit="86.6" upper_limit="111.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="269"/>
                    <count group_id="O3" value="259"/>
                    <count group_id="O4" value="264"/>
                    <count group_id="O5" value="241"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="900.5" lower_limit="788.0" upper_limit="1028.9"/>
                    <measurement group_id="O2" value="801.0" lower_limit="701.5" upper_limit="914.6"/>
                    <measurement group_id="O3" value="2316.2" lower_limit="2023.5" upper_limit="2651.4"/>
                    <measurement group_id="O4" value="1041.3" lower_limit="910.8" upper_limit="1190.4"/>
                    <measurement group_id="O5" value="461.6" lower_limit="401.2" upper_limit="531.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="268"/>
                    <count group_id="O3" value="261"/>
                    <count group_id="O4" value="265"/>
                    <count group_id="O5" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196.8" lower_limit="174.9" upper_limit="221.6"/>
                    <measurement group_id="O2" value="169.6" lower_limit="150.7" upper_limit="190.8"/>
                    <measurement group_id="O3" value="380.8" lower_limit="337.9" upper_limit="429.1"/>
                    <measurement group_id="O4" value="255.8" lower_limit="227.2" upper_limit="288.0"/>
                    <measurement group_id="O5" value="122.2" lower_limit="108.4" upper_limit="137.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="263"/>
                    <count group_id="O4" value="266"/>
                    <count group_id="O5" value="258"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.6" lower_limit="140.8" upper_limit="183.3"/>
                    <measurement group_id="O2" value="139.1" lower_limit="122.0" upper_limit="158.7"/>
                    <measurement group_id="O3" value="312.8" lower_limit="273.9" upper_limit="357.1"/>
                    <measurement group_id="O4" value="260.6" lower_limit="228.4" upper_limit="297.3"/>
                    <measurement group_id="O5" value="89.6" lower_limit="78.4" upper_limit="102.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="267"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="264"/>
                    <count group_id="O4" value="270"/>
                    <count group_id="O5" value="269"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.2" lower_limit="116.9" upper_limit="147.2"/>
                    <measurement group_id="O2" value="121.5" lower_limit="108.3" upper_limit="136.4"/>
                    <measurement group_id="O3" value="341.7" lower_limit="304.3" upper_limit="383.6"/>
                    <measurement group_id="O4" value="120.8" lower_limit="107.7" upper_limit="135.4"/>
                    <measurement group_id="O5" value="61.3" lower_limit="54.6" upper_limit="68.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                    <count group_id="O2" value="269"/>
                    <count group_id="O3" value="263"/>
                    <count group_id="O4" value="270"/>
                    <count group_id="O5" value="271"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.8" lower_limit="33.2" upper_limit="43.0"/>
                    <measurement group_id="O2" value="31.9" lower_limit="28.0" upper_limit="36.3"/>
                    <measurement group_id="O3" value="62.3" lower_limit="54.7" upper_limit="71.1"/>
                    <measurement group_id="O4" value="86.9" lower_limit="76.4" upper_limit="98.9"/>
                    <measurement group_id="O5" value="30.7" lower_limit="27.0" upper_limit="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="269"/>
                    <count group_id="O3" value="263"/>
                    <count group_id="O4" value="270"/>
                    <count group_id="O5" value="261"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.1" lower_limit="76.4" upper_limit="94.7"/>
                    <measurement group_id="O2" value="80.9" lower_limit="72.7" upper_limit="90.0"/>
                    <measurement group_id="O3" value="199.4" lower_limit="179.0" upper_limit="222.2"/>
                    <measurement group_id="O4" value="150.4" lower_limit="135.2" upper_limit="167.4"/>
                    <measurement group_id="O5" value="73.7" lower_limit="66.1" upper_limit="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 58</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="264"/>
                    <count group_id="O2" value="266"/>
                    <count group_id="O3" value="260"/>
                    <count group_id="O4" value="268"/>
                    <count group_id="O5" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.4" lower_limit="138.0" upper_limit="175.1"/>
                    <measurement group_id="O2" value="149.8" lower_limit="133.1" upper_limit="168.6"/>
                    <measurement group_id="O3" value="380.2" lower_limit="337.3" upper_limit="428.6"/>
                    <measurement group_id="O4" value="183.7" lower_limit="163.3" upper_limit="206.7"/>
                    <measurement group_id="O5" value="76.8" lower_limit="68.0" upper_limit="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24</title>
        <description>Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Seroconversion to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were defined as a titer &gt;=41, 24, 34, 39, 24, 18, 12, 16, and 12 mMU/mL, respectively. These cutoffs differ from analyses performed on samples collected up to Month 13; the antibody persistence analysis employed a new version of the assay.</description>
        <time_frame>Month 24</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV types, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24</title>
          <description>Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Seroconversion to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were defined as a titer &gt;=41, 24, 34, 39, 24, 18, 12, 16, and 12 mMU/mL, respectively. These cutoffs differ from analyses performed on samples collected up to Month 13; the antibody persistence analysis employed a new version of the assay.</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV types, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="301"/>
                <count group_id="O3" value="300"/>
                <count group_id="O4" value="300"/>
                <count group_id="O5" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV Type 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="259"/>
                    <count group_id="O3" value="252"/>
                    <count group_id="O4" value="249"/>
                    <count group_id="O5" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4" lower_limit="96.0" upper_limit="99.6"/>
                    <measurement group_id="O2" value="96.9" lower_limit="94.0" upper_limit="98.7"/>
                    <measurement group_id="O3" value="99.2" lower_limit="97.2" upper_limit="99.9"/>
                    <measurement group_id="O4" value="99.6" lower_limit="97.8" upper_limit="100"/>
                    <measurement group_id="O5" value="94.0" lower_limit="90.1" upper_limit="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="260"/>
                    <count group_id="O3" value="252"/>
                    <count group_id="O4" value="249"/>
                    <count group_id="O5" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0" lower_limit="95.4" upper_limit="99.4"/>
                    <measurement group_id="O2" value="95.8" lower_limit="92.6" upper_limit="97.9"/>
                    <measurement group_id="O3" value="99.6" lower_limit="97.8" upper_limit="100"/>
                    <measurement group_id="O4" value="98.8" lower_limit="96.5" upper_limit="99.8"/>
                    <measurement group_id="O5" value="94.8" lower_limit="91.1" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="269"/>
                    <count group_id="O3" value="259"/>
                    <count group_id="O4" value="264"/>
                    <count group_id="O5" value="241"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="96.7" upper_limit="99.8"/>
                    <measurement group_id="O2" value="99.6" lower_limit="97.9" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O4" value="99.6" lower_limit="97.9" upper_limit="100"/>
                    <measurement group_id="O5" value="99.6" lower_limit="97.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="268"/>
                    <count group_id="O3" value="261"/>
                    <count group_id="O4" value="265"/>
                    <count group_id="O5" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" lower_limit="96.2" upper_limit="99.6"/>
                    <measurement group_id="O2" value="95.9" lower_limit="92.8" upper_limit="97.9"/>
                    <measurement group_id="O3" value="98.9" lower_limit="96.7" upper_limit="99.8"/>
                    <measurement group_id="O4" value="99.2" lower_limit="97.3" upper_limit="99.9"/>
                    <measurement group_id="O5" value="95.0" lower_limit="91.6" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="263"/>
                    <count group_id="O4" value="266"/>
                    <count group_id="O5" value="258"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.0" lower_limit="94.2" upper_limit="98.7"/>
                    <measurement group_id="O2" value="94.8" lower_limit="91.4" upper_limit="97.1"/>
                    <measurement group_id="O3" value="98.5" lower_limit="96.2" upper_limit="99.6"/>
                    <measurement group_id="O4" value="97.7" lower_limit="95.2" upper_limit="99.2"/>
                    <measurement group_id="O5" value="91.5" lower_limit="87.4" upper_limit="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="267"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="264"/>
                    <count group_id="O4" value="270"/>
                    <count group_id="O5" value="269"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="95.2" upper_limit="99.2"/>
                    <measurement group_id="O2" value="96.6" lower_limit="93.7" upper_limit="98.4"/>
                    <measurement group_id="O3" value="99.2" lower_limit="97.3" upper_limit="99.9"/>
                    <measurement group_id="O4" value="98.9" lower_limit="96.8" upper_limit="99.8"/>
                    <measurement group_id="O5" value="94.8" lower_limit="91.4" upper_limit="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                    <count group_id="O2" value="269"/>
                    <count group_id="O3" value="263"/>
                    <count group_id="O4" value="270"/>
                    <count group_id="O5" value="271"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.4" lower_limit="84.0" upper_limit="92.0"/>
                    <measurement group_id="O2" value="85.9" lower_limit="81.1" upper_limit="89.8"/>
                    <measurement group_id="O3" value="93.9" lower_limit="90.3" upper_limit="96.5"/>
                    <measurement group_id="O4" value="96.7" lower_limit="93.8" upper_limit="98.5"/>
                    <measurement group_id="O5" value="82.7" lower_limit="77.6" upper_limit="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="269"/>
                    <count group_id="O3" value="263"/>
                    <count group_id="O4" value="270"/>
                    <count group_id="O5" value="261"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6" lower_limit="93.7" upper_limit="98.4"/>
                    <measurement group_id="O2" value="95.2" lower_limit="91.9" upper_limit="97.4"/>
                    <measurement group_id="O3" value="99.2" lower_limit="97.3" upper_limit="99.9"/>
                    <measurement group_id="O4" value="99.3" lower_limit="97.3" upper_limit="99.9"/>
                    <measurement group_id="O5" value="97.3" lower_limit="94.6" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 58</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="264"/>
                    <count group_id="O2" value="266"/>
                    <count group_id="O3" value="260"/>
                    <count group_id="O4" value="268"/>
                    <count group_id="O5" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="96.7" upper_limit="99.8"/>
                    <measurement group_id="O2" value="99.6" lower_limit="97.9" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O5" value="96.0" lower_limit="92.9" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36</title>
        <description>Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
        <time_frame>Month 36</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV types, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36</title>
          <description>Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Antibody titers were expressed as milli Merck units/mL (mMU/mL).</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV types, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="301"/>
                <count group_id="O3" value="300"/>
                <count group_id="O4" value="300"/>
                <count group_id="O5" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV Type 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="236"/>
                    <count group_id="O2" value="254"/>
                    <count group_id="O3" value="246"/>
                    <count group_id="O4" value="240"/>
                    <count group_id="O5" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209.6" lower_limit="184.9" upper_limit="237.6"/>
                    <measurement group_id="O2" value="160.1" lower_limit="141.9" upper_limit="180.7"/>
                    <measurement group_id="O3" value="401.2" lower_limit="354.8" upper_limit="453.7"/>
                    <measurement group_id="O4" value="232.2" lower_limit="205.1" upper_limit="263.0"/>
                    <measurement group_id="O5" value="133.8" lower_limit="117.3" upper_limit="152.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="236"/>
                    <count group_id="O2" value="255"/>
                    <count group_id="O3" value="246"/>
                    <count group_id="O4" value="240"/>
                    <count group_id="O5" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.7" lower_limit="117.6" upper_limit="152.1"/>
                    <measurement group_id="O2" value="115.2" lower_limit="101.8" upper_limit="130.3"/>
                    <measurement group_id="O3" value="308.2" lower_limit="271.8" upper_limit="349.6"/>
                    <measurement group_id="O4" value="159.1" lower_limit="140.0" upper_limit="180.7"/>
                    <measurement group_id="O5" value="82.9" lower_limit="72.4" upper_limit="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="263"/>
                    <count group_id="O3" value="253"/>
                    <count group_id="O4" value="255"/>
                    <count group_id="O5" value="222"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="673.8" lower_limit="582.8" upper_limit="779.1"/>
                    <measurement group_id="O2" value="592.6" lower_limit="514.7" upper_limit="682.4"/>
                    <measurement group_id="O3" value="1534.3" lower_limit="1328.8" upper_limit="1771.5"/>
                    <measurement group_id="O4" value="792.4" lower_limit="686.7" upper_limit="914.4"/>
                    <measurement group_id="O5" value="368.9" lower_limit="316.4" upper_limit="430.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="255"/>
                    <count group_id="O4" value="256"/>
                    <count group_id="O5" value="239"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.9" lower_limit="140.8" upper_limit="179.4"/>
                    <measurement group_id="O2" value="141.7" lower_limit="125.9" upper_limit="159.4"/>
                    <measurement group_id="O3" value="276.4" lower_limit="245.3" upper_limit="311.6"/>
                    <measurement group_id="O4" value="206.5" lower_limit="183.3" upper_limit="232.7"/>
                    <measurement group_id="O5" value="104.1" lower_limit="92.0" upper_limit="117.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="261"/>
                    <count group_id="O3" value="257"/>
                    <count group_id="O4" value="258"/>
                    <count group_id="O5" value="235"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.8" lower_limit="111.4" upper_limit="146.5"/>
                    <measurement group_id="O2" value="106.9" lower_limit="93.5" upper_limit="122.1"/>
                    <measurement group_id="O3" value="218.0" lower_limit="190.6" upper_limit="249.4"/>
                    <measurement group_id="O4" value="205.9" lower_limit="180.0" upper_limit="235.5"/>
                    <measurement group_id="O5" value="74.6" lower_limit="64.8" upper_limit="85.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="261"/>
                    <count group_id="O3" value="258"/>
                    <count group_id="O4" value="261"/>
                    <count group_id="O5" value="246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.0" lower_limit="94.1" upper_limit="119.5"/>
                    <measurement group_id="O2" value="95.7" lower_limit="85.1" upper_limit="107.5"/>
                    <measurement group_id="O3" value="240.4" lower_limit="213.8" upper_limit="270.3"/>
                    <measurement group_id="O4" value="95.5" lower_limit="85.0" upper_limit="107.3"/>
                    <measurement group_id="O5" value="52.2" lower_limit="46.3" upper_limit="58.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="250"/>
                    <count group_id="O2" value="263"/>
                    <count group_id="O3" value="257"/>
                    <count group_id="O4" value="261"/>
                    <count group_id="O5" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6" lower_limit="26.9" upper_limit="35.0"/>
                    <measurement group_id="O2" value="26.8" lower_limit="23.6" upper_limit="30.4"/>
                    <measurement group_id="O3" value="43.6" lower_limit="38.3" upper_limit="49.7"/>
                    <measurement group_id="O4" value="66.1" lower_limit="58.1" upper_limit="75.2"/>
                    <measurement group_id="O5" value="27.3" lower_limit="23.9" upper_limit="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="263"/>
                    <count group_id="O3" value="257"/>
                    <count group_id="O4" value="261"/>
                    <count group_id="O5" value="239"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.2" lower_limit="59.1" upper_limit="74.0"/>
                    <measurement group_id="O2" value="63.4" lower_limit="56.8" upper_limit="70.7"/>
                    <measurement group_id="O3" value="143.2" lower_limit="128.3" upper_limit="159.9"/>
                    <measurement group_id="O4" value="115.9" lower_limit="103.9" upper_limit="129.3"/>
                    <measurement group_id="O5" value="61.5" lower_limit="54.8" upper_limit="68.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 58</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="261"/>
                    <count group_id="O3" value="255"/>
                    <count group_id="O4" value="259"/>
                    <count group_id="O5" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.8" lower_limit="111.1" upper_limit="142.5"/>
                    <measurement group_id="O2" value="119.2" lower_limit="105.6" upper_limit="134.5"/>
                    <measurement group_id="O3" value="265.3" lower_limit="234.8" upper_limit="299.8"/>
                    <measurement group_id="O4" value="143.0" lower_limit="126.7" upper_limit="161.5"/>
                    <measurement group_id="O5" value="64.7" lower_limit="56.9" upper_limit="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36</title>
        <description>Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Seroconversion to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were defined as a titer &gt;=41, 24, 34, 39, 24, 18, 12, 16, and 12 mMU/mL, respectively. These cutoffs differ from analyses performed on samples collected up to Month 13; the antibody persistence analysis employed a new version of the assay.</description>
        <time_frame>Month 36</time_frame>
        <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV types, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O2">
            <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
            <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O3">
            <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
            <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
          </group>
          <group group_id="O4">
            <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
            <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
          <group group_id="O5">
            <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
            <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36</title>
          <description>Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Seroconversion to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were defined as a titer &gt;=41, 24, 34, 39, 24, 18, 12, 16, and 12 mMU/mL, respectively. These cutoffs differ from analyses performed on samples collected up to Month 13; the antibody persistence analysis employed a new version of the assay.</description>
          <population>All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV types, and 4) had no protocol violations that would interfere with evaluation of the immune response.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="301"/>
                <count group_id="O3" value="300"/>
                <count group_id="O4" value="300"/>
                <count group_id="O5" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV Type 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="236"/>
                    <count group_id="O2" value="254"/>
                    <count group_id="O3" value="246"/>
                    <count group_id="O4" value="240"/>
                    <count group_id="O5" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.3" lower_limit="91.8" upper_limit="97.7"/>
                    <measurement group_id="O2" value="91.3" lower_limit="87.2" upper_limit="94.5"/>
                    <measurement group_id="O3" value="99.2" lower_limit="97.1" upper_limit="99.9"/>
                    <measurement group_id="O4" value="97.9" lower_limit="95.2" upper_limit="99.3"/>
                    <measurement group_id="O5" value="92.1" lower_limit="87.6" upper_limit="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="236"/>
                    <count group_id="O2" value="255"/>
                    <count group_id="O3" value="246"/>
                    <count group_id="O4" value="240"/>
                    <count group_id="O5" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1" lower_limit="90.2" upper_limit="96.7"/>
                    <measurement group_id="O2" value="92.9" lower_limit="89.1" upper_limit="95.8"/>
                    <measurement group_id="O3" value="99.2" lower_limit="97.1" upper_limit="99.9"/>
                    <measurement group_id="O4" value="98.8" lower_limit="96.4" upper_limit="99.7"/>
                    <measurement group_id="O5" value="92.1" lower_limit="87.6" upper_limit="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="263"/>
                    <count group_id="O3" value="253"/>
                    <count group_id="O4" value="255"/>
                    <count group_id="O5" value="222"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2" lower_limit="94.3" upper_limit="98.9"/>
                    <measurement group_id="O2" value="98.5" lower_limit="96.2" upper_limit="99.6"/>
                    <measurement group_id="O3" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O4" value="99.2" lower_limit="97.2" upper_limit="99.9"/>
                    <measurement group_id="O5" value="98.2" lower_limit="95.5" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="255"/>
                    <count group_id="O4" value="256"/>
                    <count group_id="O5" value="239"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6" lower_limit="92.2" upper_limit="97.8"/>
                    <measurement group_id="O2" value="94.3" lower_limit="90.7" upper_limit="96.8"/>
                    <measurement group_id="O3" value="97.6" lower_limit="94.9" upper_limit="99.1"/>
                    <measurement group_id="O4" value="97.3" lower_limit="94.4" upper_limit="98.9"/>
                    <measurement group_id="O5" value="90.8" lower_limit="86.4" upper_limit="94.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="261"/>
                    <count group_id="O3" value="257"/>
                    <count group_id="O4" value="258"/>
                    <count group_id="O5" value="235"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.0" lower_limit="90.2" upper_limit="96.6"/>
                    <measurement group_id="O2" value="91.2" lower_limit="87.1" upper_limit="94.3"/>
                    <measurement group_id="O3" value="96.5" lower_limit="93.5" upper_limit="98.4"/>
                    <measurement group_id="O4" value="97.7" lower_limit="95.0" upper_limit="99.1"/>
                    <measurement group_id="O5" value="86.0" lower_limit="80.8" upper_limit="90.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="261"/>
                    <count group_id="O3" value="258"/>
                    <count group_id="O4" value="261"/>
                    <count group_id="O5" value="246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.0" lower_limit="90.3" upper_limit="96.6"/>
                    <measurement group_id="O2" value="96.9" lower_limit="94.1" upper_limit="98.7"/>
                    <measurement group_id="O3" value="99.2" lower_limit="97.2" upper_limit="99.9"/>
                    <measurement group_id="O4" value="98.1" lower_limit="95.6" upper_limit="99.4"/>
                    <measurement group_id="O5" value="91.9" lower_limit="87.7" upper_limit="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="250"/>
                    <count group_id="O2" value="263"/>
                    <count group_id="O3" value="257"/>
                    <count group_id="O4" value="261"/>
                    <count group_id="O5" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6" lower_limit="78.4" upper_limit="88.0"/>
                    <measurement group_id="O2" value="81.4" lower_limit="76.1" upper_limit="85.9"/>
                    <measurement group_id="O3" value="87.9" lower_limit="83.3" upper_limit="91.7"/>
                    <measurement group_id="O4" value="91.2" lower_limit="87.1" upper_limit="94.3"/>
                    <measurement group_id="O5" value="77.8" lower_limit="72.1" upper_limit="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="263"/>
                    <count group_id="O3" value="257"/>
                    <count group_id="O4" value="261"/>
                    <count group_id="O5" value="239"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.5" lower_limit="89.7" upper_limit="96.3"/>
                    <measurement group_id="O2" value="93.9" lower_limit="90.3" upper_limit="96.5"/>
                    <measurement group_id="O3" value="98.8" lower_limit="96.6" upper_limit="99.8"/>
                    <measurement group_id="O4" value="97.7" lower_limit="95.1" upper_limit="99.2"/>
                    <measurement group_id="O5" value="95.0" lower_limit="91.4" upper_limit="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 58</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="261"/>
                    <count group_id="O3" value="255"/>
                    <count group_id="O4" value="259"/>
                    <count group_id="O5" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0" lower_limit="95.3" upper_limit="99.3"/>
                    <measurement group_id="O2" value="99.2" lower_limit="97.3" upper_limit="99.9"/>
                    <measurement group_id="O3" value="100" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O4" value="98.8" lower_limit="96.7" upper_limit="99.8"/>
                    <measurement group_id="O5" value="94.8" lower_limit="91.1" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse Events: Up to Month 37; Non-injection site adverse events: up to Day 15 following any vaccination; Injection site adverse events: up to Day 5 following any vaccination</time_frame>
      <desc>Participants at risk for adverse events includes those who were vaccinated and had safety follow-up data</desc>
      <group_list>
        <group group_id="E1">
          <title>Girls 9 to 14 Years V503 at Months 0 and 6</title>
          <description>Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
        </group>
        <group group_id="E2">
          <title>Boys 9 to 14 Years V503 at Months 0 and 6</title>
          <description>Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
        </group>
        <group group_id="E3">
          <title>Girls and Boys 9 to 14 Years V503 at Months 0 and 12</title>
          <description>Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.</description>
        </group>
        <group group_id="E4">
          <title>Girls 9 to 14 Years V503 at Months 0, 2, and 6</title>
          <description>Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
        </group>
        <group group_id="E5">
          <title>Young Women 16 to 26 Years V503 at Months 0, 2, and 6</title>
          <description>Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="296"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="293"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Wolff-Parkinson-White syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Chikungunya virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Encephalitis autoimmune</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Premature delivery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="296"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="293"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="90" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="65" subjects_affected="49" subjects_at_risk="294"/>
                <counts group_id="E2" events="31" subjects_affected="28" subjects_at_risk="296"/>
                <counts group_id="E3" events="52" subjects_affected="41" subjects_at_risk="293"/>
                <counts group_id="E4" events="81" subjects_affected="53" subjects_at_risk="300"/>
                <counts group_id="E5" events="148" subjects_affected="80" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="294"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="296"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="293"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="300"/>
                <counts group_id="E5" events="19" subjects_affected="16" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

